High Expression of PD-L1 and PD-L2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors

To evaluate the expression of programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) in ocular adnexal sebaceous carcinoma (OASC), and to appraise these findings within the context of recent comparable studies.

Source: American Journal of Ophthalmology - July 26, 2020 Category: Opthalmology Authors: Natalie Wolkow, Frederick A. Jakobiec, Amir H. Afrogheh, Sara I. Pai, William C. Faquin Tags: Original Articles Source Type: research